Perficient: Drug Development

NOVEMBER 20, 2024

By combining meta-prompts, ground truth datasets, and automated evaluation, this approach ensures continuous improvement, scalability, and adaptability to new challenges, resulting in a more reliable and efficient classification system. References For further reading on MTC-LLM, the following papers and blogs provide valuable insights Brown, T.

Engineering 52

Engineering International Production 52

Common Sense for Drug Policy Blog

JULY 14, 2025

Arch Toxicol 94 , 1085–1133 (2020). Knowledge of the mechanism of action and potential clinical complications of designer drugs is key for healthcare workers who treat intoxicated patients." dwf_admin Mon, 07/14/2025 - 12:03 Source Luethi, D., Liechti, M.E. Designer drugs: mechanism of action and adverse effects.

Drugs 52

Drugs Research 52

DrugBank

JUNE 18, 2025

In 2020, the FDA halted Johnson & Johnson’s COVID-19 vaccine production at a contract manufacturing facility after discovering quality control issues. Regulatory bodies require strict adherence to Good Manufacturing Practices (GMPs) to ensure that drugs are consistently produced at high quality.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

Drug Target Review

JULY 7, 2025

USDA (2020). In the future, the most effective and ethical research won’t rely on tradition – it will be driven by technology, transparency and trust. References Animal Legal Defense Fund v. Federal ruling on USDA primate welfare petition, 2023. National Research Council. Guide for the Care and Use of Laboratory Animals. Front Pharmacol.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

Science Daily: Pharmacology News

APRIL 23, 2025

They report that carbon dioxide and methane output from just 111 companies cost the world economy $28 trillion from 1991 to 2020, with the five top-emitting firms linked to $9 trillion of those losses. The researchers use the tool to provide the first causal estimate of economic losses due to extreme heat driven by emissions.

Research 278

Research 278

Drug Target Review

APRIL 7, 2025

2020) Structural and functional characterization of G proteincoupled receptors with deep mutational scanning, eLife , 9. References Sun D, et al. 2022) Why 90% of clinical drug development fails and how to improve it?, Acta Pharmaceutica Sinica B , 12(7), pp. doi:10.1016/j.apsb.2022.02.002. 2022.02.002. Jones EM, et al. doi:10.7554/elife.54895.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

Alta Sciences

JULY 3, 2025

ABOUT THE AUTHOR: LISA SANFORD Lisa Sanford joined Altasciences in 2020 and is currently the Vice President of Business Development. Get in touch with me or one of my colleagues to see how our innovative solutions can speed up your drug development process.

Small Molecule 52

Small Molecule Drug Development Pharmaceuticals Science 52

thought leadership

JULY 11, 2025

The CRLs were issued in response to applications submitted to FDA for approval of drugs or biological products between 2020 and 2024, marking a departure in the Agency's approach to sharing information that historically has not been made public.

FDA 52

FDA Production Drugs Science 52

PPD

DECEMBER 16, 2024

Clinical trial volume: Since 2020, registered studies have surged by 50% , leading to fierce competition for resources, patients and trial sites. Roadblocks Todays drug development environment is burdened by these increasing delays, with 45% of sponsors reporting longer timelines compared to two years ago.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

Drugs.com

JULY 10, 2025

Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as replies to drug and biological product applications submitted to the agency from 2020 to 2024.The.

FDA 162

FDA Drugs Production 162

Broad Institute

APRIL 5, 2025

In 2016, 2020, and 2021, he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and was named one of Natures 10 researchers in the world.

Science 144

Science Clinical Trials DNA Disease 144

Common Sense for Drug Policy Blog

NOVEMBER 15, 2024

2020 , van Amsterdam et al., When users consume illicit drugs of unknown content, quality, and dosage, their risk of overdose and other adverse health events increases significantly ( Singh et al., Even innocuous fillers can be harmful if administered in novel or unintended ways ( Cook et al., 2021 , Sehdev et al., 2022 , Green et al.,

Marketing 52

Marketing Drugs 52

New Drug Approvals

JULY 25, 2025

2020, 117, 24285−24293. (75) 2020, 117,24285−24293. September 2020). September 2020). Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ (October 2020). .; Ortlund, E. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

LifeSciVC

JULY 8, 2025

The exuberance of 2020–2021 has given way to a more constrained, unpredictable landscape. Blaber’s model, shaped by the demands of high-risk missions, emphasizes that when doctrine breaks down, leadership must be anchored in purpose and informed by trust. That same dynamic increasingly defines biotech.

Hospitals 54

Hospitals Small Molecule Science Nurses 54

thought leadership

JULY 24, 2025

On July 10th, 2025, the FDA announced its decision to publish over 200 Complete Response Letters (CRLs) issued between 2020 and 2024. This decision marks a seismic shift in the way our industry approaches regulatory challenges.

FDA 52

FDA Drugs Compliance 52

Codon

NOVEMBER 3, 2024

Cell (2020). They zeroed in on halicin , a drug with broad-spectrum potential that had previously been trialed to treat diabetes but proved inefficacious in that regard. coli plated onto media containing halicin or ciprofloxacin antibiotics, after 7 days of incubation. Credit: Stokes J.M.

Vaccine 113

Vaccine Trials Therapies Treatment 113

New Drug Approvals

APRIL 25, 2025

World Health Organization (2020). Food and Drug Administration Approves FoundationOne Liquid CDx as a Companion Diagnostic for Itovebi (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation” (Press release). Foundation Medicine. 11 October 2024. hdl : 10665/340680.

FDA 57

FDA FDA Approval Therapies Trials 57

The Premier Consulting Blog

APRIL 13, 2025

9] ICH Harmonised Guideline S5(R3) (2020): Detection of reproductive and developmental toxicity for human pharmaceuticals. [link] [7] H.R.2565 2565 – 117th Congress (2021-2022): FDA Modernization Act of 2021 | Congress.gov | Library of Congress. [8] Focus Areas: Model-Informed Product Development.

Animal Testing 52

Animal Testing FDA Drug Development Production 52

SugarCone Biotech

MARCH 24, 2025

Proc Natl Acad Sci U S A 115: E2068-E2076. doi: 10.1073/pnas.1716266115 1716266115 8. Izquierdo et al. Front Immunol 15: 1497118. doi: 10.3389/fimmu.2024.1497118 2024.1497118 9. Demetriou et al. doi: 10.1038/s41590-020-0770-x 10. Ikemizu et al. Proc Natl Acad Sci U S A 96: 4289-4294. doi: 10.1073/pnas.96.8.4289 96.8.4289 11. Rennert et al.

Immune Response 64

Immune Response Therapies Treatment Disease 64

Codon

JUNE 5, 2025

3 The duo later shared the 2020 Nobel Prize in Chemistry for their discovery. Class 1 CRISPR-Cas RNPs contain multiple proteins each and have also been utilized for genome editing, though not as thoroughly as class 2 systems.

DNA 81

DNA RNA Clinical Trials Engineering 81

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Like many other biotechnology firms, it’s seen its stock price fall significantly during a sector-wide pullback, with shares losing more than three quarters of their value since 2020. Still, a deal Nuvation cut last year to acquire AnHeart Therapeutics has given it a chance to rebound.

FDA 270

FDA Drugs Therapies Science 270

Drug Target Review

JUNE 5, 2025

American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. 28 JANUARY 2020. The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. Br J Haematol. 2010;149(5):768-774. Chou S, et al. Blood Advances.

Disease 52

Disease Treatment Therapies Nurses 52

New Drug Approvals

MAY 9, 2025

2] [4] Pharmacology Pharmacodynamics Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , specifically targeting the estrogen receptor alpha (ER), which is the biological target of endogenous estrogens like estradiol. [1] 1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1]

FDA 62

FDA Pharmacokinetics Therapies Treatment 62

The Pharma Data

JULY 3, 2025

Biologic drug sales in Canada reached $10 billion in 2020 , representing nearly one-third of all pharmaceutical expenditures in the country, according to Health Canada. The increasing global incidence of cancer and expanding use of chemotherapy continue to drive demand for supportive care drugs such as pegfilgrastim.

Marketing 52

Marketing Biosimilars Pharmaceutical Companies Pharmaceuticals 52

LifeSciVC

JUNE 12, 2025

Building medicines by activating biological pathways As I joined the Company in Q4 2020 as its CEO, I had a vision of creating protein variants to activate biological pathways. Atlas Venture and NEA were early believers, incubating Korro Bio and providing the initial capital and strategic support needed to turn this vision into reality.

RNA 67

RNA Protein Expression DNA Science 67

New Drug Approvals

JUNE 15, 2025

24 September 2024.

FDA 57

FDA Treatment Clinical Trials Production 57

New Drug Approvals

JUNE 29, 2025

2020/0062765) was dissolved in ethanol (604 mL) at 50℃. Example 5: Preparation and Characterization of Crystalline Form A of Compound 1 Free Base [0212] Compound 1 HCl (75.5 obtained by using the method described in Example 5 of U.S. Application Publication No. Sodium hydroxide (68.1 g) was added to the above solution.

International 62

International FDA Clinical Trials Treatment 62

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). Palmateer N, Hamill V, Bergenstrom A, Bloomfield H, Gordon L, Stone J, Fraser H, Seyler T, Duan Y, Tran R, Trayner K, Biggam C, Smith S, Vickerman P, Hickman M, Hutchinson S. Int J Drug Policy.

Drugs 119

Drugs Treatment Disease Science 119

Codon

NOVEMBER 1, 2024

A 200x drop in price over twenty-five years is impressive, but these costs have now flatlined — or have even risen — since 2020. Today, the same feat can be done for about $0.10. The cost to synthesize full-length genes (blue) or small DNA snippets, called oligonucleotides (red), over time.

DNA 132

DNA RNA Molecular Biology Laboratories 132

BioPharma Drive: Drug Pricing

JULY 18, 2025

Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. Food and Drug Administration headquarters in Silver Spring, Md.,

Therapies 159

Therapies FDA Clinical Trials Licensing 159

Chemical Biology and Drug Design

DECEMBER 30, 2024

In 2020, two selective RET inhibitors, selpercatinib and pralsetinib were approved by the US FDA. Therefore, 8w and 8s might be promising lead compounds. ABSTRACT RET (Rearranged during transfection) kinase is a validated target for non-small cell lung cancer (NSCLC). However, high treatment costs and clinically acquired resistance (e.g.,

FDA 100

FDA Therapies Treatment Research 100

New Drug Approvals

APRIL 18, 2025

8 May 2020). . “OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia” Journal of the Endocrine Society. 6 (Supplement_1): A618. doi : 10.1210/jendso/bvac150.1281. PMC 9625506. 4 (Supplement_1): OR25-03.

FDA 62

FDA FDA Approval Drugs Trials 62

New Drug Approvals

APRIL 19, 2025

4] Landiolol can be used as first-line treatment for acute ventricular rate control in patients with atrial fibrillation (Level I recommendation- 2020 Guidelines of the European Society of Cardiology [15] ). Mode of action The drug acts as an ultra-short-acting 1-selective blocking agent. 56 (5): 5557. doi : 10.1536/ihj.15-102. PMID 26346519.

FDA 62

FDA Clinical Trials Treatment Trials 62

New Drug Approvals

JULY 8, 2025

US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020. NCT03073967 ^ 2020-004940-27 ^ Biswas, S.; It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. 316 (23): 2495–2503. doi : 10.1001/jama.2016.18189. 2016.18189.

Virus 62

Virus DNA Clinical Trials Treatment 62

BioPharma Drive: Drug Pricing

JULY 9, 2025

Published July 9, 2025 By Kristin Jensen post share post print email license Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., Alamy Merck & Co.

Clinical Trials 277

Clinical Trials Drugs Therapies Licensing 277

LifeSciVC

DECEMBER 5, 2024

Other than Flagship’s fund with the monster Moderna position in 2020-2022, I don’t think that’s ever been done before in the history of the biotech industry.

Marketing 84

Marketing RNA Drugs Science 84

BioPharma Drive: Drug Pricing

JULY 14, 2025

In 2020, Partners Group flipped its ownership stake to Mubadala. The company has changed hands among private equity investors multiple times over the last decade or so. Frazier Healthcare Partners acquired it from Catalent Pharma in 2012 and sold a majority stake to Partners Group four years later.

Production 152

Production Drugs Therapies Clinical Trials 152